Brainstorm Cell Therapeutics Inc.
BCLI
$0.642
-$0.0032-0.50%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.71M | 7.31M | 7.04M | 8.68M | 9.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.90M | 12.31M | 11.69M | 13.31M | 16.30M |
| Operating Income | -11.90M | -12.31M | -11.69M | -13.31M | -16.30M |
| Income Before Tax | -11.45M | -11.09M | -11.62M | -14.23M | -12.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.45 | -11.09 | -11.62 | -14.23 | -12.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.45M | -11.09M | -11.62M | -14.23M | -12.75M |
| EBIT | -11.90M | -12.31M | -11.69M | -13.31M | -16.30M |
| EBITDA | -11.68M | -12.08M | -11.45M | -13.06M | -16.04M |
| EPS Basic | -1.82 | -2.02 | -2.35 | -3.46 | -3.36 |
| Normalized Basic EPS | -1.14 | -1.26 | -1.47 | -2.16 | -2.10 |
| EPS Diluted | -1.82 | -2.02 | -2.35 | -3.46 | -3.36 |
| Normalized Diluted EPS | -1.14 | -1.26 | -1.47 | -2.16 | -2.10 |
| Average Basic Shares Outstanding | 25.98M | 22.11M | 20.08M | 17.81M | 15.45M |
| Average Diluted Shares Outstanding | 25.98M | 22.11M | 20.08M | 17.81M | 15.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |